https://www.rarediseases-conference.com/wp-content/uploads/2022/02/DSCF1884b-320x320.jpg
Vice President NovaQuest Capital Management

Devin ROSENTHAL


Dr. Rosenthal has broad operational and strategic experience across a range of therapeutic areas, stages of development, and company types within the biopharmaceutical industry. As a member of the NovaQuest Product Finance deal team, he is responsible for investment due diligence, deal sourcing, and transaction structuring.

Prior to NovaQuest, Devin was a Senior Consultant at Triangle Insights Group, a boutique life sciences strategy consulting firm, where he focused on corporate strategy, due diligence, mergers and acquisitions, and commercial forecasting. His earlier industry experience includes work in product development and regulatory affairs at Rho, a mid-size contract research organization; companion diagnostics at Novartis Oncology; and clinical development at Boston Biomedical Inc, all following postdoctoral training at Tufts University’s Molecular Oncology Research Institute.

Devin holds a PhD in cellular and molecular biology from the University of Michigan, an executive MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill (finance concentration), and a BS in biology from the University of North Carolina at Wilmington.

Contact us


Registrations & Sponsorships
Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]
 
Info & Content
Natalia Toubanaki, T: +30 210 6617 777 (ext. 289), +30 6947936708, E: [email protected]
Valya Kyritsi, T: +30 210 6617 777 (ext. 227), E: [email protected] 

BOUSSIAS

  338. Kleisthenous Str. 15344, Gerakas, Attiki, Greece
  +30 210 6617777
  +30 210 6617778
  www.boussias.com